IP Library › Granted Patent US 11,193,164
Granted Patent B2
US 11,193,164 · App. 15/989,100 · Granted Dec 7, 2021

Methods of diagnosing and treating cancer targeting extrachromosomal DNA

Inventors: Paul Mischel (Los Angeles, CA); Prashant Mali (San Diego, CA); Vineet Bafna (San Diego, CA); Kristen Turner (San Diego, CA); Viraj Deshpande (San Diego, CA); Doruk Beyter (San Diego, CA)
Assignees: The Regents of the University of California; Ludwig Institute for Cancer Research Ltd
C12Q1/6841C12Q1/6886C12Q2600/106
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,193,164
App. No.
15/989,100
Granted
Dec 7, 2021
Kind
B2
Abstract

Provided herein are, inter alia, methods and compositions to detect, monitor and treat cancer, wherein the cancer includes amplified extrachromosomal oncogenes. The methods are useful for personalized treatment and exploit differential expression of amplified extrachromosomal oncogenes in cancer cells versus healthy cells.

Claims (29)

1. A method of detecting an amplified extrachromosomal oncogene in a human subject in need thereof, said method comprising:

(i) obtaining a biological sample from a human subject;

(ii) sequencing the genome of said human subject from said biological sample;

(iii) detecting whether an amplified extrachromosomal oncogene is present in said biological sample; and,

(iv) determining the number of circular extrachromosomal DNA (ecDNA) particles per cancer cell.

2. The method of claim 1 , wherein said amplified extrachromosomal oncogene forms part of a circular extrachromosomal DNA.

3. The method of claim 1 , wherein said detecting comprises:

(1) detecting an intracellular location of said amplified extrachromosomal oncogene relative to a standard control;

(2) mapping said circular extrachromosomal DNA; and

(3) detecting genetic heterogeneity of said circular extrachromosomal DNA relative to a standard control.

4. A method of detecting an amplified extrachromosomal oncogene in a cancer subject undergoing treatment for cancer, said method comprising:

(i) obtaining a first biological sample from said cancer subject undergoing treatment for cancer; and

(ii) sequencing the genome of said human subject from said biological sample;

(iii) detecting in said first biological sample a first level of an amplified extrachromosomal oncogene; and,

(iv) determining the number of circular extrachromosomal DNA (ecDNA) particles per cancer cell.

5. The method of claim 4 comprising after step (ii)-(iv):

(v) obtaining a second biological sample from said subject;

(vi) detecting in said second biological sample a second level of said amplified extrachromosomal oncogene;

(vii) determining the number of circular extrachromosomal DNA (ecDNA) particles per cell in said second biological sample; and,

(viii) comparing said first level to said second level.

6. The method of claim 4 , wherein said amplified extrachromosomal oncogene forms part of a circular extrachromosomal DNA.

7. The method of claim 5 , wherein said detecting comprises:

(1) detecting an intracellular location of said amplified extrachromosomal oncogene relative to a standard control;

(2) detecting a level of said circular extrachromosomal DNA relative to a standard control;

(3) mapping said circular extrachromosomal DNA; and

(4) detecting genetic heterogeneity of said circular extrachromosomal DNA.

8. The method of claim 1 , wherein said biological sample is a blood-derived biological sample, a urine-derived biological sample, a tumor sample, or a tumor fluid sample.

9. The method of claim 1 , wherein said determining the number of circular extrachromosomal DNA (ecDNA) particles per cell comprises preparing metaphase spreads of cells from said biological sample.

10. The method of claim 1 , wherein said amplified extrachromosomal oncogene is EGFR, c-Myc, N-Myc, cyclin D1, ErbB2, CDK4, CDK6, BRAF, MDM2, or MDM4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2021
From: MISCHEL, PAUL; TURNER, KRISTEN
To: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
Reel/Frame 056120/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2021
From: MALI, PRASHANT; BAFNA, VINEET; BEYTER, DORUK; DESHPANDE, VIRAJ
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 056122/0658 →
Continuity (3)
Provisional Application 62559111 · Sep 15, 2017
Provisional Application 62510375 · May 24, 2017
Related Publication 20180355416A1 · Dec 13, 2018
Cited By (1)
US 12,246,017